Medicare Stand-Alone Plans to End Zero Premiums in 2027
The federal government will terminate its premium stabilization program, causing costs to rise for millions of beneficiaries.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Do you expect your household's prescription drug costs to become more expensive in the coming year?
No stand-alone Medicare Part D prescription drug plans will offer zero-dollar monthly premiums in 2027. This change follows the government's decision to end the Part D Premium Stabilization Demonstration program a year earlier than scheduled.
Why it matters
By ending the demonstration program, the federal government removes the subsidy floors and premium caps that previously kept costs lower for enrollees. This shift forces millions of beneficiaries to contend with significantly higher monthly expenses for their coverage.
The average monthly premium for stand-alone drug plans will rise from $34 in 2026 to $51 in 2027, an increase of 50 percent. Meanwhile, the standard Part D deductible will increase from $615 to $700 during the same period.
The players
Medicare
This federal health insurance program provides coverage for individuals aged 65 and older as well as younger people with specific disabilities.
The details
The termination of the Part D Premium Stabilization Demonstration removes the subsidy program that provided $9.8 billion to plan sponsors between 2025 and 2026. Consequently, 99.8 percent of stand-alone drug plan enrollees will face a deductible in 2027, while those remaining in plans will encounter median coinsurance rates of 25 percent for preferred brands and 35 percent for non-preferred drugs.
Timeline
2025: Demonstration capped monthly premium increases at $35.
2026: Demonstration capped monthly premium increases at $50.
December 7, 2026: Deadline for Medicare plan open enrollment.
2027: First year with no zero-premium stand-alone drug plans.
Market Landscape
The end of the Part D Premium Stabilization Demonstration marks a departure from recent federal efforts to artificially cap prescription drug costs. This shift significantly differentiates the pricing environment for stand-alone plans from Medicare Advantage options that continue to use rebate dollars to subsidize premiums.
Beneficiaries will likely see their monthly premiums rise sharply as subsidies are removed, necessitating a careful review of available plans during the upcoming enrollment period. While stand-alone plans face rising costs, Medicare Advantage prescription drug plans are currently estimated to average $7 per month.
The takeaway
Beneficiaries should prepare for higher out-of-pocket costs and higher deductibles in 2027 due to the removal of federal subsidy floors. Reviewing all available plan options before the December 7, 2026 deadline is essential to mitigate the impact of these premium hikes.
Further reading
Learn more about coverage changes in the Healthcare section.
Live Poll
Do you expect your household's prescription drug costs to become more expensive in the coming year?
